Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
172.14
-0.81 (-0.47%)
At close: Jun 27, 2025, 4:00 PM
172.22
+0.08 (0.05%)
After-hours: Jun 27, 2025, 5:12 PM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
According to 16 professional analysts, the 12-month price target for Ascendis Pharma stock ranges from a low of $153 to a high of $289. The average analyst price target of $218.19 forecasts a 26.75% increase in the stock price over the next year.
Price Target: $218.19 (+26.75%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 6 | 6 | 7 | 9 | 9 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $215 → $224 | Buy | Maintains | $215 → $224 | +30.13% | Jun 13, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $201 → $216 | Strong Buy | Maintains | $201 → $216 | +25.48% | Jun 9, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $196 → $201 | Strong Buy | Maintains | $196 → $201 | +16.77% | Jun 3, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $200 | Buy | Reiterates | $200 | +16.18% | May 12, 2025 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $180 → $250 | Hold → Buy | Upgrades | $180 → $250 | +45.23% | May 5, 2025 |
Financial Forecast
Revenue This Year
636.57M
from 363.64M
Increased by 75.05%
Revenue Next Year
1.13B
from 636.57M
Increased by 78.14%
EPS This Year
-4.27
from -6.53
EPS Next Year
1.31
from -4.27
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 842.1M | 1.6B | 2.6B | ||
| Avg | 636.6M | 1.1B | 1.7B | ||
| Low | 500.4M | 836.1M | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.6% | 157.6% | 127.2% | ||
| Avg | 75.1% | 78.1% | 52.0% | ||
| Low | 37.6% | 31.4% | 10.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.91 | 6.06 | 11.87 | ||
| Avg | -4.27 | 1.31 | 7.23 | ||
| Low | -7.53 | -3.05 | 1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 804.9% | ||
| Avg | - | - | 451.5% | ||
| Low | - | - | 51.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.